Grant Awarded for Maximizing CAR T in Ovarian Cancer Treatment

Daniel J. Powell Jr., MD, of Pathology and Laboratory Medicine, and Michael Farwell, MD, of Radiology, received UG3/UH3 grant funding of more than $6 million to develop a platform that would allow controlled delivery of immunomodulatory agents to maximize anti-tumor activity—and safety—in CAR T cell therapy that would also provide functional imaging readouts on the therapeutic processes that occur during treatment of ovarian cancer.